Networking Projects
Funded under ERA PerMed JTC2018 and JTC2022 and EP PerMed JTC2024
The Voice PM project aims to organise a networking event which addresses the vital need for meaningful patient involvement in translational research for personalised medicine. While personalised medicine offers groundbreaking diagnostic and therapeutic potential, its successful integration into healthcare requires the early, continuous inclusion of patient perspectives. Currently, patient involvement often remains limited or fragmented; Voice PM aims to reposition patients as key stakeholders, data owners, and active innovation partners. By uniting researchers, clinicians, policymakers, and patient organisations, the initiative explores best practices for embedding engagement throughout the research cycle, from initial study design to clinical implementation. The project seeks to establish a shared framework that identifies barriers and enablers to ensure equitable, patient-centered research, ultimately fostering the sustainable integration of personalised medicine into global healthcare systems.
- Aim: To strengthen collaboration in personalised cancer medicine by bringing together ongoing and previously funded ERA PerMed and EP PerMed projects at a networking event on 16 June 2026 in Brussels, Belgium.
- Projects involved: The event will include, among others, ImmuneT-ME (Interrogation of the immune-microenvironment of T-cell malignancies, EP PerMed JTC2024), IPerGlio (Improving personalised glioblastoma care by intertwined immunomics and artificial intelligence approaches, ERA PerMed JTC2022), and JAKSTAT-TARGET (Novel individualised therapies in JAK/STAT driven T-cell malignancies, ERA PerMed JTC2018), alongside additional EP PerMed JTC2024 projects.
- Objectives: To foster exchange of best practices, stimulate cross-project learning, and identify scientific and translational synergies across different funding streams.
- Main translational stakeholder: Cancer Patients Europe (CPE), ensuring patient perspectives and real-world relevance are embedded throughout the discussions.
- International stakeholders: Participation from other Horizon Europe and EU4Health projects, as well as researchers, clinicians, policymakers, and industry representatives.
- Expected impact: To accelerate translation of research outcomes into patient centred innovation and policy-relevant insights in personalised medicine.
24-25 June 2026
VOICE PM Networking Event on Meaningful Patient Involvement in Translational Personalised Medicine Research
Cancer Patients Europe (CPE) is pleased to invite researchers, clinicians, patient representatives, policymakers, regulatory bodies, and industry stakeholders, to participate in the VOICE PM Networking Event: Meaningful Patient Involvement in Translational Personalised Medicine Research, taking place on 24-25 June 2026 in Brussels, Belgium. Organised as part of the VOICE PM networking project within the framework of the European Partnership for Personalised Medicine (EP PerMed).
The event will provide a unique opportunity for participants from previously funded ERA PerMed and EP PerMed projects, as well as Horizon Europe projects, patient organisations, healthcare professionals, researchers, policymakers, regulatory bodies, HTA experts, and industry representatives to exchange experiences and discuss practical approaches to patient engagement. Through presentations, discussions, and networking activities, participants will explore successful examples of patient involvement, identify common challenges, and contribute to recommendations that can support more patient-centred research and innovation.
The event is structured over two days:
- Wednesday, 24 June 2026 from 14:00 to 18:00 – Rue de l’Industrie 24, 1040 Brussels
- Thursday, 25 June 2026 from 09:00 to 17:30 – Skyline, Rue de Trèves 74, 1040 Brussels.
The second day will be integrated into the Cancer Patients Europe Annual Meeting.
We look forward to welcoming you to Brussels for two days of discussion, collaboration, and knowledge exchange dedicated to strengthening meaningful patient involvement in personalised medicine research.